Reported Earlier, Quest Diagnostics Prices $1.85B Senior Notes Due 2027, 2029, And 2034
Reported Earlier, Quest Diagnostics Prices $1.85B Senior Notes Due 2027, 2029, And 2034
奎斯特診療公司早前報告的消息：發行總額爲18.5億美元的2027年、2029年和2034年到期的高級票據。
Quest Diagnostics Incorporated (NYSE:DGX) (the "Company"), a leader in diagnostic information services, today announced the pricing of a public offering of $400 million aggregate principal amount of its 4.600% senior notes due 2027 (the "2027 notes"), $600 million aggregate principal amount of its 4.625% senior notes due 2029 (the "2029 notes") and $850 million aggregate principal amount of its 5.000% senior notes due 2034 (the "2034 notes," and together with the 2027 notes and the 2029 notes, the "notes") under Quest Diagnostics' shelf registration statement.
奎斯特診療公司（紐交所：DGX）是一家診斷信息服務領域的領導者，今天宣佈根據其擱置登記聲明，發行40000萬美元的4.600％優先票據（"2027票據"），發行60000萬美元的4.625％優先票據（"2029票據"）和發行85000萬美元的5.000％優先票據（"2034票據"，連同2027票據和2029票據共同構成"票據"）的公開發行定價。